Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
City of Hope Medical Center
LigaChem Biosciences, Inc.
Intensity Therapeutics, Inc.
Novartis
Novartis
H. Lee Moffitt Cancer Center and Research Institute